PHARMO Institute for Drug Outcomes Research

If you're planning to attend the 2024 Alzheimer's Association International Conference (AAIC) in a couple of weeks, be sure to catch our poster, "Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case-control study using Dutch primary care data" on Sunday, July 28, 2024, 08:00–16:15. Learn more at https://aaic.alz.org/ #alzheimers #AAIC2024 #dementia #primarycaredata

New research from our own Eline Houben highlights the importance of coordination between general practitioners (GPs) and obstetricians/gynecologists in the provision of routine medical care during pregnancy. Of 140,976 pregnancies in the Netherlands between 2004 and 2020, registration in The Teratology Information Service, the knowledge centre of Lareb on safety of drugs used before and during pregnancy and during breastfeeding, was only available for 13%. The limited registration introduces a risk of prescribing teratogenic medications and increases the likelihood of pregnant women experiencing an adverse event. Registration rates appear to improve in later years. Increased collaboration between GPs and midwives is strongly encouraged. Read the full research brief in English at https://lnkd.in/eq7SVzgj or in Dutch at https://lnkd.in/eh-9pwig   #realworldevidence #realworlddata #carecoordination #drugsafety #adversevent #adverseventmonitoring #pharmacovigilance #teratogenic #riskmanagement #publichealth

We are proud to be presenting at the upcoming Royal Statistical Society (RSS) International Conference 2024. Be sure to add our rapid-fire talk to your diary, Enhancing the identification and profiling of patients with heart failure in a population-based cohort through linkage of primary and secondary care data, on September 4, 15:10-15:50pm. For more information about the conference, visit https://lnkd.in/e6mUTj5C #RSS2024 #heartfailure #statistics #caredata #patientprofiling

We are looking forward to the upcoming 2024 Alzheimer's Association International Conference (AAIC). If you'll be in Philadelphia for the conference, be sure to catch our poster, "Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case-control study using Dutch primary care data" on Sunday, July 28, 2024, 8:00 AM – 4:15 PM EDT For more information about the conference, visit https://aaic.alz.org/ #alzheimers #AAIC2024 #dementia #primarycaredata

If you're at the DIA Global Annual Meeting in San Diego, connect with our colleagues on-site, including Naomi Boxall and Steven Weisman PhD, via the DIA meeting app. Don't miss tomorrow's forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring: - Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity - Naomi Boxall, PhD, General Manager, PHARMO Institute - Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA - Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University - Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company For more information, visit https://buff.ly/3WSqtDH #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety

The DRUG INFORMATION ASSOCIATION (DIA) Global Annual Meeting is around the corner! If you'll be there, connect with our colleagues on-site, including Naomi Boxall and Steven Weisman PhD. Be sure to catch our forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring: - Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity - Naomi Boxall, PhD, General Manager, PHARMO Institute - Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA - Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University - Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company During the forum we will explore the critical need for longitudinal data in drug safety research, examining the strengths and limitations of different data collection approaches and examine collaborative opportunities with regulators and organizations, such as SIGMA, to address these research needs and enhance patient care. For more information on this session, visit https://buff.ly/44V8RJs Reach out to our colleagues in the DIA meeting app or email contact@lumanity.com to schedule time to meet with us on-site. #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety

The DIA Global Annual Meeting is just a couple of weeks away! If you're planning to be there, be sure to connect with our colleagues on-site, including Steve Weisman and Naomi Boxall through the DIA meeting app or by emailing contact@lumanity.com to schedule time to meet on-site. Don't miss the forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity, Naomi Boxall, PhD, General Manager, PHARMO Institute, Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA, Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University, and Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company The forum will explore the critical need for longitudinal data in drug safety research, examining the strengths and limitations of different data collection approaches and examine collaborative opportunities with regulators and organizations, such as SIGMA, to address these research needs and enhance patient care. For more information on this session, visit https://buff.ly/3KoloeT #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety

We are excited to be at the table at the upcoming hybrid workshop, Joint HMA/EMA Big Data Steering Group workshop on RWE methods, taking place June 14 at the EMA premises in Amsterdam as well as online. Hilda de Jong will be joining other stakeholders to share views of the RWE reflection paper, priorities for further regulatory guidance development and collaboration beyond the reflection paper, and novel RWE methods in regulatory decision-making. The workshop is targeted towards regulatory bodies, academia, the pharmaceutical industry, health technology assessment (HTA), patients and healthcare professionals. For more information, and to register for virtual attendance, visit https://lnkd.in/gejCu6D7 #EMA #EuropeanMedicinesAgency #HMA #RWE #regulatory #HTA #realworldevidence #decisionmaking

We are looking forward to the upcoming DRUG INFORMATION ASSOCIATION (DIA) Global Annual Meeting next month! If you're attending, be sure to connect with our colleagues on-site, including Naomi Boxall and Steven Weisman PhD. Don't miss our forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring: – Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity – Naomi Boxall, PhD, General Manager, PHARMO Institute – Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA – Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University – Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company During the forum we will explore the critical need for longitudinal data in drug safety research, examining the strengths and limitations of different data collection approaches and examine collaborative opportunities with regulators and organizations, such as SIGMA, to address these research needs and enhance patient care. For more information on this session, visit https://buff.ly/4bt4LdV Reach out to our colleagues in the DIA meeting app or e-mail contact@lumanity.com to schedule time to meet with us on-site. #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety

Check out our new article with our partners at Lumanity https://buff.ly/3UU2QYJ and be sure to catch our forum at the upcoming DIA Global Annual Meeting, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events, during which we will explore the critical need for longitudinal data in drug safety research as well as the strengths and limitations of different data collection approaches. #realworlddata #RWD #patientsafety #drugsafety #outcomesresearch #epidemiology #healthcareoutcomes #DIA2024